Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in India / NCT07420634
Recruiting Observational

Multilevel Ecological and COM-B Determinants of Medication Adherence in Adults With Diabetes

NCT07420634 · tracked via the Priya Life Science India tracker
Sponsor
University of Malaya
Phase
Observational
Started
2025-12-15
Last updated
2026-02-19

Condition(s) studied

Diabetes MellitusDiabetes Mellitus Type 2Medication Adherence

Investigational drug(s) / intervention(s)

Multilevel Ecological Determinants of Medication Adherence

Multilevel Ecological Determinants of Medication Adherence: Assessment of contextual and behavioral determinants associated with medication adherence among adults with diabetes receiving routine clinical care. Determinants include individual-level factors (medication literacy, beliefs about medicines), interpersonal factors (family involvement, social support), healthcare interaction factors (communication quality, regimen complexity), and structural/access-related factors (availability, affordability, distance). These exposures are measured through validated questionnaires and prescription review during a single outpatient encounter. No intervention is assigned as part of the study.

Study summary

This observational study aims to understand why some adults with diabetes find it difficult to take their medicines as prescribed. Medication adherence is essential for controlling blood sugar levels and preventing complications, yet many patients face challenges that go beyond personal motivation.

The study will examine multiple factors that may influence medication-taking behavior, including patients' understanding of their medicines, beliefs about treatment, family and social support, communication with healthcare providers, and practical issues such as medicine cost, availability, and distance to care. These factors will be analyzed using a structured behavioral framework to better understand how capability, opportunity, and motivation contribute to adherence.

By identifying the most important barriers and supports across different levels, this research aims to provide evidence that can guide patient-centered care strategies and improve medication adherence in diabetes management.

Eligibility

Sex
ALL
Min age
18 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria: * Adults aged 18 years or older * Diagnosed with at least one chronic disease (e.g., diabetes mellitus, hypertension, cardiovascular disease, chronic respiratory disease, chronic kidney disease) for a minimum duration of six months * Prescribed long-term medication therapy * Able to understand and respond to the study questionnaire * Willing to provide written informed consent Exclusion Criteria: * Patients with acute medical conditions requiring immediate care * Individuals with severe cognitive impairment or psychiatric illness that would preclude reliable participation * Patients who are terminally ill * Patients unwilling to participate or provide consent

Primary outcome measure(s)

  • Medication Adherence — Single assessment at enrollment (Day 1)
    Medication adherence assessed using the 12-item Adherence to Refills and Medications Scale (ARMS-12). Total scores range from 12 to 48, with higher scores indicating lower adherence.

Trial sites (1)

FacilityCityRegionStatus
MM Superspeciality Hospital, Maharishi Markandeshwar (Deemed to be University) Ambāla Haryana Recruiting

More University of Malaya trials in India

The Liver Cirrhosis Cognitive Decline Scale (LiCCoS) Recruiting

Other trials for the same condition

Evaluating Urine Isoniazid Testing to Detect Nonadherence to Tuberculosis Medications in India Enrolling by invitation
Effect of Empagliflozin vs Linagliptin on Glycemic Outcomes,Renal Outcomes & Body Composition in Renal Transplant Recipients With Diabetes Mellitus Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07420634 on ClinicalTrials.gov ↗ ← All trials in India